Skip to main content
. 2014 Feb 4;14:57. doi: 10.1186/1471-2334-14-57

Table 1.

Age-specific average annual frequency and notification rates of IDs in Norway in 2007 to 2011

Notifiable infectious disease *
Average annual frequency
 Average annual notification rate (range)/100,000 inhabitants
 NRR 7 (range)
  Total ≥65 years Total <5 years 5-19 years 20-64 years ≥65 years 65+/20-64
Overall
 15870
 1792
 332 (307–362)
 330 (285–407)
 330 (276–399)
 351 (312–411)
 253 (236–280)
 0.7 (0.6-0.9)
   Invasive bacterial diseases (IBD)
  
  
  
  
  
  
  
  
Pneumococcal IBD
 818
 411
 17.1 (14.9-20.4)
 13.0 (9.1-19.7)
 2.3 (1.2-3.1)
 12.1 (10.1-14.9)
 58.1 (51.6-66.4)
 4.8 (4.4-5.1)
Group B Streptococcal IBD
 178
 78
 3.7 (3.4 -3.9)
 14.1 (12.3-15.9)
 0.2 (0.0-0.4)
 2.0 (1.8-2.2)
 11.0 (9.8-12.5)
 5.6 (4.5-7.6)
Group A Streptococcal IBD
 163
 68
 3.4 (2.8-3.6)
 2.6 (1.0)
 0.7 (0.4-0.9)
 2.8 (2.1-3.2)
 9.5 (8.8-10.7)
 3.4 (2.7-4.5)
Haemophilus influenzae IBD
 81
 40
 1.7 (1.5-1.8)
 2.2 (1.4-3.4)
 0.4 (0.2-0.5)
 1.1 (0.8-1.4)
 5.7 (4.4-7.0)
 5.6 (3.5-8.9)
Meningococcal IBD
 37
 5.8
 0.8 (0.6-0.9)
 3.2 (2.3-4.1)
 1.3 (0.9-2.0)
 0.3 (0.3-0.4)
 0.8 (0.3-1.1)
 2.4 (1.0-3.6)
   Food- and waterborne diseases1
  
  
  
  
  
  
  
  
Campylobacteriosis
 2839
 217
 59.2 (55.0-60.9)
 62.4 (47.7-77.7)
 36.2 (31.1-41.6)
 73.4 (70.5-75.6)
 30.5 (25.1-38.3)
 0.4 (0.4-0.5)
Salmonellosis
 1485
 125
 31.0 (26.0-40.8)
 48.2 (36.9-56.9)
 22.4 (18.1-30.0)
 35.3 (28.0-47.5)
 17.6 (12.3-21.8)
 0.5 (0.4-0.7)
Listeriosis
 31
 20
 0.7 (0.4-1.0)
 0.3 (0.0-0.7)
 0.0 (0.0-0.0)
 0.4 (0.1-0.7)
 2.8 (2.3-4.2)
 15.6 (3.8-37.5)
Enteropathogenic E. coli-enteritis 2
 272
 9.2
 5.6 (2.3-9.3)
 61.1 (15.2-115.9)
 2.2 (0.8-3.2)
 2.0 (1.8-2.2)
 1.3 (0.4-2.2)
 0.6 (0.2-1.0)
Giardiasis
 192
 9.0
 4.0 (3.6-5.0)
 7.9 (4.8-10.1)
 3.4 (2.8-3.7)
 4.5 (3.9-5.8)
 1.3 (0.8-1.9)
 0.3 (0.2-0.3)
Shigellosis
 144
 6.4
 3.0 (2.7-3.3)
 3.7 (1.9-5.5)
 1.8 (1.4-2.4)
 3.8 (3.3-4.7)
 0.90 (0.3-1.4)
 0.2 (0.1-0.4)
Paratyphoid fever
 16
 1.0
 0.3 (0.2-0.4)
 0.3 (0.0-0.7)
 0.3 (0.0-0.9)
 0.4 (0.2-0.5)
 0.1 (0.0-0.4)
 0.4 (0.0-1.1)
Yersiniosis
 59
 2.8
 1.2 (1.1-1.5)
 3.4 (2.2-4.4)
 1.0 (0.7-1.3)
 1.3 (1.0-1.7)
 0.4 (0.0-0.7)
 0.3 (0. 0–0.6)
Typhoid fever
 17
 0.2
 0.4 (0.2-0.6)
 0.6 (0.3-1.7)
 0.5 (0.4-0.5)
 0.4 (0.2-0.7)
 0.0 (0.0-0.1)
 0.0 (0.0-0.2)
   Vaccine preventable diseases
  
  
  
  
  
  
  
  
Pertussis
 4328
 383
 90.4 (66.3-115.5)
 56.3 (42.8-63.8)
 211.5 (162.0-277.6)
 63.4 (44.0-82.1)
 54.2 (34.8-70.4)
 0.9 (0.7-1.0)
Mumps 3
 16
 1.4
 0.3 (0.2-0.5)
 0.1 (0.0-0.6)
 0.3 (0.1-1.0)
 0.4 (0.3-0.5)
 0.2 (0.1-0.3)
 0.6 (0.3-1.0)
Tetanus
 1.0
 1.0
 0.0 (0.0-0.0)
 0.0 (0.0-0.0)
 0.0 (0.0-0.0)
 0.0 (0.0-0.0)
 0.1 (0.0-0.3)
 ∞ (∞)
   Antibiotic-resistant bacteria
  
  
  
  
  
  
  
  
MRSA infection 3, 4
 420
 92
 8.7 (7.3-11.4)
 11.0 (8.8-13.3)
 6.5 (5.1-9.4)
 8.2 (6.6-11.4)
 13 (11.4-16.1)
 1.6 (1.2-2.1)
MRSA carriage 3, 4
 384
 82
 8.0 (5.6-9.9)
 16.3 (8.6-21.4)
 4.6 (1.5-6.6)
 7.3 (4.9-9.2)
 12.2 (10.6-14.8)
 1.7 (1.2-2.7)
Vancomycin-resistant enterococci 3
 51
 33
 1.0 (0.1-4.3)
 0.1 (0.1-0.3)
 0.1 (0.0-0.4)
 0.6 (0.1-2.3)
 4.5 (0.6-19.4)
 6.5 (4.0-8.6)
Penicillin-resistant pneumococci 3
 11
 1.4
 0.2 (0.0-0.5)
 1.1 (0.0-3.5)
 0.1 (0.0-0.2)
 0.2 (0.0-0.4)
 0.2 (0.1-0.3)
 1.7 (0.4-4.0)
   Zoonosis/vector-borne diseases
  
  
  
  
  
  
  
  
Lyme borreliosis 3
 297
 57
 6.2 (5.1-7.3)
 5.6 (4.6-6.2)
 8.9 (6.3-10.9)
 4.9 (3.6-6.4)
 8.1 (6.3-9.8)
 1.7 (1.5-1.9)
Tularaemia
 66
 10
 1.4 (0.3-3.6)
 0.7 (0.0-2.3)
 1.0 (0.2-2.8)
 1.5 (0.3-3.9)
 1.4 (0.1-3.8)
 0.8 (0.4-1.0)
HFRS 5/Nephropathia epidemica
 40
 4.6
 0.8 (0.4-1.6)
 0.1 (0.0-0.3)
 0.3 (0.1-0.6)
 1.2 (0.6-2.3)
 0.7 (0.3-1.2)
 0.7 (0.2-1.0)
Malaria
 32
 1.0
 0.7 (0.6-0.8)
 0.2 (0.0-0.3)
 0.2 (0.1-0.3)
 1.0 (0.9-1.2)
 0.1 (0.0-0.4)
 0.1 (0.0-0.4)
   Blood-borne/STI
  
  
  
  
  
  
  
  
Hepatitis C 3, 6
 2270
 36
 47.2 (33.7-70.5)
 2.3 (1.0-4.8)
 5.1 (4.0-7.0)
 76.1 (53.6-114.1)
 5.0 (4.6-5.8)
 0.1 (0.1-0.1)
Hepatitis B (chronic carriage)
 693
 13
 14.4 (14.3-17.4)
 0.7 (0.0-1.4)
 8.5 (6.4-11.0)
 20.9 (15.7-24.9)
 1.8 (1.0-2.3)
 0.1 (0.1-0.1)
Gonorrhoea
 266
 4.2
 5.5 (4.6-6.3)
 0.1 (0.0-0.3)
 1.4 (0.9-1.6)
 8.7 (7.4-9.8)
 0.6 (0.1-1.2)
 0.1 (0.0-0.1)
Hepatitis A
 36
 3.0
 0.7 (0.4-1.0)
 1.1 (0.7-2.3)
 0.9 (0.6-1.4)
 0.7 (0.3-1.1)
 0.4 (0.1-1.0)
 0.6 (0.4-1.4)
HIV infection
 256
 2.6
 5.3 (4.9-5.9)
 0.9 (0.0-2.1)
 0.6 (0.4-0.9)
 8.6 (8.0-9.5)
 0.4 (0.3-0.6)
 0.0 (0.0-0.1)
AIDS
 33
 2.2
 0.7 (0.4-0.9)
 0.0 (0.0-0.0)
 0.0 (0.0-0.2)
 1.0 (0.6-1.4)
 0.3 (0.0-1.0)
 0.3 (0.0-1.0)
Hepatitis B (acute infection)
 71
 1.4
 1.5 (0.6-2.6)
 0.1 (0.0-0.3)
 0.6 (0.1-1.3)
 2.2 (0.9-3.8)
 0.2 (0.0-0.4)
 0.1 (0.0-0.2)
Syphilis
 88
 0.8
 1.8 (1.2-2.6)
 0.0 (0.0-0.0)
 0.1 (0.0-0.6)
 3.0 (1.9-4.4)
 0.1 (0.0-0.3)
 0.0 (0.0-0.1)
   Other diseases
  
  
  
  
  
  
  
  
Tuberculosis
 336
 38
 7.0 (6.5-7.5)
 1.5 (0.7-2.1)
 4.4 (3.5-4.6)
 8.8 (7.7-9.7)
 5.3 (4.5-6.9)
 0.6 (0.5-0.9)
Encephalitis
 179
 17
 3.7 (2.8-6.4)
 8.8 (5.5-17.2)
 2.4 (1.4-4.9)
 3.9 (2.9-6.5)
 2.4 (1.9-3.2)
 0.6 (0.5-0.8)
Legionellosis
 40
 15
 0.8 (0.7-1.0)
 0.0 (0.0-0.0)
 0.0 (0.0-0.0)
 0.9 (0.7-1.1)
 2.1 (1.5-3.0)
 2.3 (1.8-3.2)
Creutzfeldt Jacob 3 9.6 7.2 0.2 (0.1-0.3) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.1 (0.0-0.1) 1.0 (0.3-1.4) 12.3 (2.0-∞)

IDs = infectious diseases.

*Note that data for botulism, cholera, rubella and brucellosis are not presented, as no such cases aged ≥65 years occurred between 2007 and 2011 (notification rate = 0/100,000).

1: Note that food- and waterborne infections can have been transmitted in other modes than through food and water, such as via infected individuals and animals.

2: Enteropathogenic E.(Escherichia) coli-enteritis includes Haemolytic Uremic Syndrome.

3: For the following diseases, notification became mandatory or the last change in notification guidelines was implemented after 1993: Mumps, MRSA infections, Lyme borreliosis (1995); Creutzfeldt Jacob (1997); MRSA carriage, vancomycin-resistant enterococci, penicillin-resistant pneumococci (2005); hepatitis C (2008).

4: MRSA = Methicillin-resistant Staphylococcus aureus.

5: HFRS = Haemorrhagic fever with renal syndrome.

6: Because hepatitis C became notifiable only since 2008, these results only include data of 2008–2011.

7: The notification rate ratio (NRR) was calculated by dividing the average notification rate in 2007–2011 among the population ≥65 years by the average notification rate among those aged 20–64 years. A NRR above 1 reflects a higher notification rate in the population ≥65 years compared to those aged 20–64 years, while a NRR below 1 reflects a lower NRR in the population ≥65 years.